Shire's SHP622 Phase 1 Study (formerly VP-20629)

Safety and Pharmacology Study of VP 20629 (now called SHP622) in Adults With FA

Ages: 18-45

Locations: Children's Hospital of Philadephia (CHOP), Emory, University of South Florida, University of Iowa, UCLA

Details: This is a Phase 1 study sponsored by Shire (formerly initiated by ViroPharma) designed to evaluate dosage and safety of VP20629, a naturally occurring small molecular weight drug compound that can prevent oxidative stress to improve mitochondrial function. Participation in this study requires both outpatient and inpatient visits. Subjects in the second arm need to stay in the hospital for 10 days. In the second arm, subjects will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.

Specific information on inclusion and exclusion criteria is available here:
Please call or email one of the sites below if you are interested in participating:

Children's Hospital of Philadelphia (CHOP), Philadelphia, PA
Principal Investigator: Dr. David Lynch
Lauren Seyer from CHOP/ Tel.: (267) 426-9738; Email:
Debbie Foerster from CHOP/ Tel.: (267) 426-7584; Email:
CHOP study ad:

Emory University, Atlanta, GA
Principal Investigator: Dr. George Wilmot
Coordinator: Rebecca McMurray, *NOTE New Phone Number* Tel: 404-712-7013; Email:
Emory study ad:

University of South Florida, Tampa, FL
Principal Investigator: Dr. Theresa Zesiewicz
Coordinator: Kevin Allison, Tel: (813) 974-5909; email:

University of Iowa, Iowa City, IA
Principal Investigator: Dr. Kathy Mathews
Coordinator: Carrie Stephan, Tel: (319) 356-2673; email:

UCLA Medical Center, Los Angeles, CA
Principal Investigator: Dr. Susan Perlman
Coordinator: Brian Clemente, Tel: (310) 794-1225; email:
UCLA study ad:

Privacy Policy      Service Terms      Contact      Charity Navigator